Abstract
Background While many clinical risk factors of trigeminal neuralgia (TN) have been identified, the genetic basis of TN is largely unknown. Here, we perform the first genome-wide association study (GWAS) for TN using three independent DNA biobanks – BioVU, the UK Biobank, and Finngen.
Objective To elucidate the genetic basis of TN.
Methods Using GWAS summary statistics generated from BioVU, the UK Biobank, and Finngen, we performed fixed-effect meta-analysis across 490,912 individuals (1,188 TN cases and 489,724 controls) to identify genetic risk factors for TN. Genome-wide significance was defined as p < 5.0×10−8.
Results We identify an intergenic locus on chromosome 1p22.2 flanked by ZNF326 and SNORD3G containing 5 SNPs (rs77449572, rs543311093, rs35117749, rs71666259, and rs116010656) reaching genome-wide significance (p < 5.0 x 10−8), where rs77449572 is the sentinel variant (p = 1.72 x 10−9). The SNP rs77449572 overlaps an enhancer element in cortex-derived neurospheres. In addition, rs71666259 and rs116010656 are located in enhancer elements in embryonic stem cells (HUES48), suggesting potential functional consequences of this locus. We also identify a second locus on chromosome 5q35.1 containing sentinel variant rs62376947 reaching genome-wide significance (p = 2.49 x 10−8).
Conclusions To our knowledge, we perform the first GWAS of TN. Future studies should be aimed at understanding the extent to which genetic variation stratifies response to neuropathic pain medication and whether genetic information may be used to identify patients who are likely to benefit (or not) from surgical intervention.
Competing Interest Statement
Dr. Gamazon receives an honorarium from the journal Circulation Research of the American Heart Association, as a member of the Editorial Board.
Funding Statement
Dr. Hale receives salary support from the National Institutes of Health (NIH, F30HL143826 and R35HG010718). Processing and imputation of genetic data was supported by a grant awarded to Dr. Hale from the Vanderbilt Institute for Clinical and Translational Research (VR53934.1). L.B. is supported by R01LM010685. Dr. Gamazon is supported by the National Human Genome Research Institute of the National Institutes of Health under Award Numbers R35HG010718 and R01HG011138. Dr. Gamazon has also significantly benefitted from a Fellowship at Clare Hall, University of Cambridge (UK) and is grateful to the President and Fellows of the college for a stimulating intellectual home.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional review board approval was provided by Vanderbilt University.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest: Dr. Gamazon receives an honorarium from the journal Circulation Research of the American Heart Association, as a member of the Editorial Board.
Disclosure of Funding: Dr. Hale receives salary support from the National Institutes of Health (NIH, F30HL143826 and R35HG010718). Processing and imputation of genetic data was supported by a grant awarded to Dr. Hale from the Vanderbilt Institute for Clinical and Translational Research (VR53934.1). L.B. is supported by R01LM010685. Dr. Gamazon is supported by the National Human Genome Research Institute of the National Institutes of Health under Award Numbers R35HG010718 and R01HG011138. Dr. Gamazon has also significantly benefitted from a Fellowship at Clare Hall, University of Cambridge (UK) and is grateful to the President and Fellows of the college for a stimulating intellectual home.
Data Availability
All data will be made available by the corresponding author, Dr. Andrew Hale (andrew.hale{at}vanderbilt.edu).
